Wellington Management Group LLP Grows Position in Immunome, Inc. $IMNM

Wellington Management Group LLP boosted its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 10.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,210,216 shares of the company’s stock after purchasing an additional 478,239 shares during the period. Wellington Management Group LLP owned about 4.59% of Immunome worth $110,404,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IMNM. Allworth Financial LP bought a new stake in Immunome in the second quarter worth about $25,000. KBC Group NV bought a new position in shares of Immunome during the first quarter valued at approximately $60,000. Strs Ohio purchased a new stake in shares of Immunome in the fourth quarter worth approximately $64,000. Assetmark Inc. raised its holdings in shares of Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares during the period. Finally, State of Wyoming bought a new stake in shares of Immunome during the 2nd quarter worth approximately $109,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Isaac Barchas sold 11,048 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the transaction, the director owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. This represents a 10.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the transaction, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. This represents a 77.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 682,310 shares of company stock worth $15,675,566. 7.21% of the stock is currently owned by company insiders.

Immunome Stock Performance

Immunome stock opened at $27.07 on Wednesday. The company has a market capitalization of $3.07 billion, a PE ratio of -10.70 and a beta of 2.13. The company has a 50 day moving average price of $24.52 and a 200-day moving average price of $22.48. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $30.06.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, analysts forecast that Immunome, Inc. will post -2.38 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on IMNM. HC Wainwright restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Truist Financial lifted their target price on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Leerink Partners lowered their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Wall Street Zen cut shares of Immunome from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Wedbush raised their price target on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.64.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.